Last reviewed · How we verify
I.v. NNC 0113-0987 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
I.v. NNC 0113-0987 (I.v. NNC 0113-0987) — Novo Nordisk A/S.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| I.v. NNC 0113-0987 TARGET | I.v. NNC 0113-0987 | Novo Nordisk A/S | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- I.v. NNC 0113-0987 CI watch — RSS
- I.v. NNC 0113-0987 CI watch — Atom
- I.v. NNC 0113-0987 CI watch — JSON
- I.v. NNC 0113-0987 alone — RSS
Cite this brief
Drug Landscape (2026). I.v. NNC 0113-0987 — Competitive Intelligence Brief. https://druglandscape.com/ci/i-v-nnc-0113-0987. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab